Drug Trial Radar · NCT03519256
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
Last checked: Nov 19, 2026Latest source record: Jun 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
142
Actual
Start
Aug 2, 2018
Primary completion
Aug 22, 2022
Study completion Aug 24, 2022
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- May 8, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.
Conditions
- Urinary Bladder Neoplasms
Interventions
NivolumabBiological
Specified dose on specified days
BCGBiological
Specified dose on specified days
BMS-986205Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
- Number of Participants With Serious Adverse Events (SAEs)Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
- Number of Participants With Adverse Events (AEs) Leading to Discontinuation of Study TreatmentTime frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
- Number of Participants Immune-Mediated Adverse Events (IMAEs)Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
- Number of Participants Who DiedTime frame: From first dose to 100 days post last dose of study treatment (an average of 45 weeks up to approximately 74 weeks)
- Number of Participants With Specific Liver Laboratory AbnormalitiesTime frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
- Number of Participants With Specific Thyroid Laboratory AbnormalitiesTime frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
- Number of Participants With Changes From Baseline Laboratory ValuesTime frame: From baseline to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
- Number of Participants With Adverse Events (AEs) by Anti-Drug- Antibody (ADA) StatusTime frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
- Number of Participants With Serious Adverse Events (SAEs) by Anti-Drug- Antibody (ADA) StatusTime frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Locations
88 sites in 15 countries. Site status is shown where the registry gives one.
Local Institution - 0044
Los Angeles, California
Local Institution - 0081
Riverside, California
Local Institution - 0087
San Francisco, California
Local Institution - 0125
Tampa, Florida
Local Institution - 0056
Hapeville, Georgia
Local Institution - 0023
New Lenox, Illinois
Wichita Urology Group
Wichita, Kansas
Local Institution - 0001
Baltimore, Maryland
Local Institution - 0077
Ann Arbor, Michigan
Local Institution - 0032
Minneapolis, Minnesota
Local Institution - 0040
Omaha, Nebraska
Local Institution - 0144
New Brunswick, New Jersey
Deleware Valley Urology, LLC
Voorhees Township, New Jersey
Local Institution - 0051
New York, New York
Local Institution - 0058
Columbus, Ohio
Local Institution - 0036
Bala-Cynwyd, Pennsylvania
Local Institution - 0049
Charleston, South Carolina
Local Institution - 0002
Myrtle Beach, South Carolina
Local Institution - 0057
Chattanooga, Tennessee
Urology Clinics Of North Texas, Pa
Dallas, Texas
Local Institution - 0048
Houston, Texas
Local Institution - 0140
Houston, Texas
Local Institution - 0047
Lubbock, Texas
Urology San Antonio Research, Pa
San Antonio, Texas
Local Institution - 0141
Seattle, Washington
Instituto Oncologico De Cordoba
Córdoba, Argentina
Local Institution - 0137
Mendoza, Argentina
Local Institution - 0068
Capital Federal, Buenos Aires, Argentina
Local Institution - 0065
Capital Federal, Distrito Federal, Argentina
Local Institution - 0089
Ciudad Autonoma Buenos Aires, Distrito Federal, Argentina
Local Institution
Viedma, Río Negro Province, Argentina
Local Institution - 0146
Camperdown, New South Wales, Australia
Local Institution - 0148
St Leonards, New South Wales, Australia
Local Institution - 0150
Rio de Janeiro, Brazil
Local Institution - 0074
São Paulo, Brazil
Local Institution - 0072
Fortaleza, Ceará, Brazil
Local Institution - 0151
Curitiba, Paraná, Brazil
Local Institution - 0073
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution
Itacorubi, Florianopolis, Santa Catarina, Brazil
Local Institution - 0078
Jaú, São Paulo, Brazil
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.